Cisplatin + Paclitaxel + Bevacizumab
Treatment for Cervical Cancer
Typical Dosage: Cisplatin 50mg/m², Paclitaxel 135mg/m², Bevacizumab 15mg/kg every 3 weeks
Effectiveness
50%
Safety Score
25%
Clinical Trials
35
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cisplatin 50mg/m², Paclitaxel 135mg/m², Bevacizumab 15mg/kg every 3 weeks
Time to Effect
Weeks to months
Treatment Duration
Until progression or unacceptable toxicity
Evidence Quality
HIGHNumber Needed to Treat (NNT)
7(Treat 7 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100,000
Monitoring:$15,000
Side Effect Mgmt:$8,000
Total Annual:$123,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$273,333
Comparison vs Cisplatin + Paclitaxel alone
Cost Difference
+$80,000/year
More expensive
QALY Difference
+0.50 QALYs
Better outcomes
Dominance
No dominance
Cisplatin + Paclitaxel + Bevacizumab Outcomes
for Cervical Cancer
Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+45%
Remission Rate
+5%
Common Side Effects
Fatigue
+85%
Nausea/Vomiting
+75%
Hair loss
+85%
Peripheral neuropathy
+60%
Bone marrow suppression
+70%
Hypertension
+40%
Gastrointestinal perforation
+3%
Fistula formation
+12%
Sources:
Active Clinical Trials
5 active trials recruiting for Cisplatin + Paclitaxel + Bevacizumab in Cervical Cancer
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer
NCT06459687RECRUITINGPHASE3
440 participants
INTERVENTIONAL
Hefei, China +4 more
Started: Nov 28, 2024
ctDNA-guided First-line Immuno-de-escalation Therapy for IVB-stage and Recurrent Cervical Cancer
NCT06878196NOT YET RECRUITINGNA
20 participants
INTERVENTIONAL
Shanghai, China
Started: Mar 10, 2025
A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
NCT06755515ENROLLING BY INVITATIONPHASE2, PHASE3
510 participants
INTERVENTIONAL
Linyi, China
Started: Sep 26, 2024
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT04982237ACTIVE NOT RECRUITINGPHASE3
445 participants
INTERVENTIONAL
Hangzhou, China +4 more
Started: Aug 27, 2021
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
NCT07216703RECRUITINGPHASE3
1.02K participants
INTERVENTIONAL
Birmingham, United States +173 more
Started: Jan 19, 2026
Completed Clinical Trials
4 completed trials for Cisplatin + Paclitaxel + Bevacizumab in Cervical Cancer
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
NCT03556839COMPLETEDPHASE3
410 participants
INTERVENTIONAL
Shreveport, United States +71 more
Started: Sep 25, 2018
Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
NCT04551950COMPLETEDPHASE1
25 participants
INTERVENTIONAL
Stanford, United States +12 more
Started: Oct 19, 2020
A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
NCT04868708COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Changsha, China +1 more
Started: Apr 1, 2021
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
NCT03635567COMPLETEDPHASE3
617 participants
INTERVENTIONAL
Anchorage, United States +148 more
Started: Oct 25, 2018
Showing 20 of 38 total trials